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Abstract
Background: Salmonellosis is one of the most important foodborne diseases and a major threat to public health.
Salmonella serotype Virchow ranks among the top five serovars in Europe.
Method: A total of 153 strains isolated from different patients from 2004 through 2009 in Switzerland were further
characterized by (i) assessing phenotypic antibiotic resistance profiles using the disk diffusion method and (ii) by
genotyping using pulsed-field gel electrophoresis (PFGE) after macrorestriction with XbaI in order to evaluate strain
relationship.
Results: The relative frequency of S. Virchow among other Salmonella serovars varied between 4th to 8th rank. The
annual incidence ranged from 0.45/100’000 in 2004 to 0.40/100’000 in 2009. A total of 48 strains (32%) were
resistant to one to 3 antimicrobials, 54 strains (36%) displayed resistance patterns to more than three antibiotics.
No trend was identifiable over the years 2004 to 2009. We found a high prevalence (62%) of nalidixic acid resistant
strains, suggesting an equally high rate of decreased fluoroqionolone susceptibility, whereas intermediate
resistance to ciprofloxacin was negligible. Two strains were extended spectrum b-lactamase (ESBL) producers.
Analysis of PFGE patterns uncovered a predominant cluster (similarity coefficient above 80%) consisting of 104 of
the 153 strains.
Conclusion: The worldwide increase of antibiotic resistances in Salmonella is an emerging public health problem.
For Switzerland, no clear trend is identifiable over the years 2004 to 2009 for S. Virchow. Antimicrobial susceptibility
and resistance profiles varied considerably within this period. Nevertheless, the situation in Switzerland coincided
with findings in other European countries. Genotyping results of this strain collection revealed no evidence for an
undetected outbreak within this time period.
Background
Non-typhoidal salmonellae are worldwide responsible
for numerous foodborne infections and are a major
threat to public health [1,2]. Based on the lipopolysac-
charide (O antigen) and the flagellar structures (H anti-
gen) Salmonella spp. are divided into greater than 2500
serotypes, of which only few obtain substantial relevance
to humans [3]. In Europe, as well as in Switzerland, Sal-
monella serotype Virchow ranks among the five most
frequent serovars and has been reported to be poultry
associated [4-9]. As with other enteritic salmonellae,
infections due to S. Virchow commonly manifest them-
selves as self-limiting gastroenteritis, but severe invasive
infections can also occur which then need antibiotic
treatment [10]. Whereas fluoroquinolones are used to
treat extraintestinal infections in adults, third generation
cephalosporins are drugs of choice in children. Alar-
mingly, in the last decade numerous European countries
reported emergence of S. Virchow strains resistant to
the above mentioned antimicrobials, leading to treat-
ment failures [9,11,12]. Resistance to quinolones is
either mediated by chromosomal mutations in genes
encoding DNA gyrase or topoisomerase IV or in genes
affecting the uptake or efflux of drugs [13]. Plasmid
associated quinolone corrupting genes such as aac(6’)-
Ib-cr or qnr etc., are also known to cause reduced sus-
ceptibility. Resistance to third generation cephalosporins
is mediated by extended spectrum b-lactamases (ESBL),
which are plasmid encoded or integron associated [14].
In this study, a total of 153 S. Virchow strains isolated
from different patients from 2004 through 2009 in
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Switzerland were further characterized by (i) assessing
phenotypic antibiotic resistance profiles using the disk
diffusion method and (ii) by genotyping using pulsed-
field gel electrophoresis (PFGE) after macrorestriction
with XbaI in order to evaluate strain relationship.
Methods
Strains
Human salmonellosis is a reportable disease in Switzer-
land and isolates have to be submitted to the National
Centre for Enteropathogenic Bacteria (NENT). The
NENT - in cooperation with the Swiss Federal Office of
Public Health - collects clinical data and carries out
final serological identification by slide agglutination with
commercial antisera according to the Kauffmann-White
scheme. Over the years 2004 through 2009, 10395 Sal-
monella strains were submitted to the NENT. From this
collection of strains 153 S. Virchow strains (1,5%) from
different patients (multiple isolates from same patient
excluded, but family members not excluded) were
selected and integrated in this study. All samples had
been collected by hospitals or family doctors.
Antimicrobial susceptibility testing
The strains were tested for antimicrobial resistance by
the disk diffusion method according to the Clinical and
Laboratory Standards Institute (CLSI) [15]. The panel of
antibiotic disks (Becton, Dickinson and Company, Mary-
land, USA) consisted of ampicillin (AM10), amoxicillin/
clavulanic acid (AMC30), cephalothin (CF30), cefotax-
ime (CTX30), ciprofloxacin (CIP5), gentamicin (GM10),
tetracycline (Te30), streptomycin (S10), chloramphenicol
(C30), kanamycin (K30), nalidixic acid (NA30), sulfa-
methoxazole (SMZ), and trimethoprim (TMP5). The
strains were classified as resistant, intermediate or sus-
ceptible to each antibiotic agent according to the CLSI
criteria [15].
For presumptive ESBL producers - strains that pro-
duced synergistic inhibition zone enlargements between
adjacent discs containing an oxyimino cephalosporin
and clavulanic acid, respectively - Etest ESBL (bioMér-
ieux, Marcy l’Etoile, France) tests, containing cefotaxime
(CT/CTL), ceftazidime (TZ/TZL), or cefepime (PM/
PML) alone and in combination with clavulanic acid,
were performed for confirmation according the manu-
facturer’s guidelines.
Genotyping
Pulsed-field gel electrophoresis (PFGE) was performed
by following the CDC PulseNet protocol http://www.
cdc.gov/pulsenet/protocols.htm with minor modifica-
tions. In brief, strains were grown on blood agar at
37°C over night. Colonies from blood agar were resus-
pended in cell suspension buffer (OD600 = 1). The
bacterial cell suspension was mixed with 400 μl of
1.4% Pulsed Field Certified Agarose (BIO-RAD,
Munich, Germany) and cells were lysed by proteinase
K treatment over night. After lysis the plugs were
washed twice for 30 min in ultrapure water and 4
times for an hour in Tris-EDTA (TE) buffer. After
washing with TE buffer, DNA agarose plugs were incu-
bated over night in the presence of XbaI (Roche, Man-
nheim, Germany) following the manufacturer ’s
instructions. Restricted DNA in plug slices was sepa-
rated in a 1% SeaKem Gold (BioConcept, Allschwil,
Switzerland) agarose gel at 6 V/cm in 0.5 M Tris-
Borate-EDTA buffer cooled to 12°C in a CHEF-DR III
system (BIO-RAD, Munich, Germany). The pulse
times were ramped from 2 to 64 sec for 20 h at an
angle of 120°. Gels were stained with ethidium bro-
mide and visualized under UV light transillumination
with Gel Doc (BIO-RAD, Munich, Germany) and ana-
lysed with BioNumerics software (Applied Maths, Sint-
Martens-Latem, Belgium). Pair wise similarities
between the XbaI pulsed-field patterns were calculated
by the DICE’s similarity coefficient. Clustering was
based on the unweighted pair-group method with
averages (UPGMA), setting tolerance and optimization
each at 1.5%. We used Salmonella Braenderup strain
H9812 (ATCC BAA 664) as a reference strain.
Results
Clinical and epidemiological data
The 153 S. Virchow strains were isolated from 124 fae-
cal samples (81%), 17 blood samples (11.1%), two urine
samples (1.3%), two swabs (1.3%), and one synovial
puncture (0.7%). For 7 strains (4.6%) the origin was
unknown. The relative frequency of S. Virchow among
other Salmonella serovars varied between 4th to 8th
rank. The annual incidence ranged from 0.45/100’000 in
2004 to 0.40/100’000 in 2009 (lowest incidence: 0.39/
100’000 in 2006, highest incidence: 0.47/100’000 in
2007).
The age of the patients was known for 99% of the iso-
lates submitted. Fourteen percent of the S. Virchow
strains were submitted from patients aged 5 years and
younger (incidence: 0.9/100’000), 3.5% from patients
aged 6 to 14 years (incidence: 0.13/100’000), 74.5% from
patients aged 15 to 65 years (incidence: 0.4/100’000) and
7% from patients older than 65 years (incidence: 0.17/
100’000). The incidence among infants of 5 years and
younger was seven fold higher than that among children
aged 6 to 14 years. The incidence of people between 15
and 65 years was three fold higher than that of children
aged 6 to 14 years. Of the patients infected with
S. Virchow 52% were female and 48% were male.
Of all patients, 35 (23%) had travelled abroad, the tra-
velling status was unknown for 117 patients (76%), and
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only one person confirmed not having visited a foreign
country within two weeks prior to infection. Eleven per-
sons (7.2%) had visited Egypt, 7 (4.6%) Thailand, 3 (2%)
India, 2 (1.3%) Kenya, 2 (1.3%) Asia. The following
countries had been visited by one person each (0.7%):
Guinea, Jordan, Senegal/Gambia, China, Sri Lanka and
Tanzania. Four patients (2.6%) affirmed having visited a
foreign country within two weeks prior to infection
start, but gave no further information about the destina-
tion. As many as 82.5% who had travelled to a foreign
country within two weeks before disease outbreak, were
between 15 and 65 years old, 7.5% were younger than 6
years, another 7.5% were aged from 6 to 14 years, and
2.5% were older than 65. Subtracting the number of
patients with travel background from the total of the
patients lowered the average incidence from 0.42/
100’000 to 0.34/100’000. Turning the attention on the
6 to 14 year old children, the incidence reduced even
from 0.13/100’000 to 0.07/100’000 by subtracting those
who stayed abroad. Regarding the 15 to 65 year old
patients, the incidence showed similar behaviour and
decreased from 0.41/100’000 to 0.3/100’000 while the
incidence of other age-groups exhibited only minor
changes.
Antimicrobial susceptibility
A high prevalence of resistant (resistant to 1 to 3 anti-
microbials) and multi drug resistant (MDR = resistant
to more than 3 antibiotics) S. Virchow strains was
detected. For calculation of percentages, intermediate
susceptibility was counted as “susceptible”. A total of 48
strains (32%) were resistant and 54 strains (36%) dis-
played MDR, whereas only 50 strains (33%) showed full
susceptibility. There is no clear trend identifiable over
the years 2004 to 2009. Antimicrobial susceptibility and
resistance profiles varied considerably (Figure 1). Thus
in 2008, 67% of all isolates exhibited MDR, and only
19% were susceptible to all antibiotic agents tested.
However, in 2009 only 25% of all strains displayed MDR
but 57% showed no resistances.
We found 62% of all S. Virchow strains resistant to nali-
dixic acid, while 98% were susceptible to ciprofloxacin,
and only 2% (3 isolates) were intermediate according to
CLSI criteria [15]. As many as 49% of the isolates were
resistant to sulfamethoxazole, 41% to trimethoprim and
36% to tetracycline. All strains were susceptible to cefotax-
ime, and only 1.3% were resistant to amoxicillin/clavulanic
acid. During the years 2004 to 2007 the resistance situa-
tion remained consistent. In 2008, for several antimicro-
bials the percentage of resistant strains was significantly
higher (p < 0.05) than in the preceding years. Interestingly,
multiple percentages during 2009 lay beneath the average
values of the years 2004 to 2009 (p < 0.05) (Figure 2).
Hence, there were no significant trends in resistance
development observable for any antibiotic.
Two S. Virchow strains (05N2379 and 06N1956) pro-
duced ESBL. Both strains tested positive with the confir-
matory Etest ESBL (ratio CT/CTL = 62,5; ratio TZ/TZL
>340; ratio PM/PML >6).
Genetic relationship among Swiss S. Virchow isolates
PFGE analysis of the 153 XbaI-digested strains revealed
104 pulsotypes with 14 to 22 DNA fragments ranging
from 20,5 kb to 1135 kb. Five and more related strains
defined the formation of a cluster. We discovered four
pattern clusters (A-D, Figure 3), when strains were con-
sidered related if their similarity coefficient exceeded
80%. There were no correlations regarding gender, year
of isolation, age-group or stay-abroad, and no other
common properties were found for isolates within a
Figure 1 Assigned to the number of antibiotic resistances (1 to 10), for each year, the number of resistant strains are constituted as
dark blue, intermediate strains as light blue columns, respectively.
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certain cluster. A number of pulsotypes incorporated
several indistinguishable isolates. Their content ranged
from 2 to 8 indistinguishable isolates (Figure 3).
Discussion
During the study period, 1.5% of all Salmonella strains
submitted to the NENT belonged to the serotype
Virchow. This amounted to a prevalence of 0.45 (2004)
to 0.40 (2009) cases per 100’000 population, and was
within the average in Europe [4,5]. For a comparison,
the prevalence of total salmonellosis in Switzerland was
26 (2004) to 25 (2009) cases per 100’000 population.
Whereas in France the annual number as well as the
corresponding rank decreased during 2005 to 2008 [5],
Figure 2 Resistance of S. Virchow strains isolated over the years 2004 trough 2009 in Switzerland. Each box shows the percentage
fraction of the resistant, intermediate and susceptible sub-population over time for one antimicrobial. Values significantly (p < 0.05) deviating
from average are marked with * (more resistant) or + (less resistant), respectively.
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in Switzerland the number of cases associated with
S. Virchow infections and its rank remained constant
from 2004 through 2009.
Conspicuously, the incidence of infected children aged 0
to 5 years was seven fold higher than that in children
older than 5 years. Reasons may be an insufficient immune
defence that lowers the minimal infective dose, as the
immune system has not yet fully developed. Regarding the
age-group from 15 to 65, we discovered a three fold higher
incidence compared to the incidence of persons aged older
Figure 3 Anamnestic data, resistance profiles and PFGE patterns of the 153 S. Virchow strains. PFGE clusters are faintly coloured and
marked A-D. Strains resistant, intermediate or susceptible to a specific antibiotic are highlighted in red, white, or green, respectively.
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than 65. This could be linked to considerable differences
in travelling activity. Thus, 25% of all patients between
15 and 65 years of age had been visiting a foreign country
within 2 weeks before infection. Even 50% of the infections
among 6 to 14 years old children were associated with tra-
velling, whereas other age-groups could hardly be linked
to a stay-abroad. Upon the present investigation, no case
control study could be performed, and, unfortunately,
exact data about travel destinations were available only
with 31 of the 153 cases. Nevertheless, 16 and 15 out of
the 31 cases could be traced back to African and Asian
countries, respectively.
In this study, S. Virchow strains isolated from blood
samples, and presumably associated with invasive mani-
festation, were enclosed. Interestingly, we did not
receive any blood samples derived from children up to
5 years. In contrast, 16% blood samples were submitted
from adult patients of the 15 to 65 age group. Similar
findings were published in 2005 from a university hospi-
tal in Crete (Greece). Galanakis and his team found 41%
of all patients infected with non-thyphoidal salmonellae
aged under 15 years, but only 4.06% suffered from an
invasive disease. Adult patients (> 15 years) suffered
twice as much from an invasive manifestation [16].
However, Parry reported about sub-Saharan Africa,
where invasive infections caused by enteritic serotypes
are particularly common in children under 5 years [17].
Reasons for such divergent findings are unknown, but
differences between developed and developing countries
seem to exist.
Genotyping revealed 104 strains with a high degree
(> 82%) of relationship, summarised in cluster A, which
constituted the major part of all isolates. Additionally,
several groups of samples were discovered, representing
indistinguishable pulsotypes. Strains belonging to cluster
A were collected within the years 2004 to 2009 and ori-
ginated from different countries. This indicates, that
these closely related isolates are highly established and
widespread.
Indistinguishable patterns give evidence to small
outbreaks or point sources, that spread a certain
strain over several years. This becomes particularly
apparent regarding non-discriminable isolates derived
from patients that stayed in the same foreign country.
As already mentioned, most of the strains from
patients with a travelling background had returned
from the North-African or Asian region. Close clonal
relationship between strains from those regions is
exemplified by two PFGE sub-clusters within the
large Cluster A. One sub-cluster is associated with
Egypt (Figure 3, strains no. 8-N1063, 9-N2543, 7-
N2080, 8-N2820, 8-N2492, 8-N2393), the other with
Thailand (Figure 3, strains no. 6-N0978, 6-N1949, 7-
N0090, 7-N0368).
The number of resistant (31.5%) and multiresistant
(35.5%) strains is considerable. Similar rates from Eur-
opean countries have already been published. In 2004 a
study performed by Meakins and co-authors revealed
73% of all S. Virchow strains resistant to at least one
antimicrobial agent [18]. Threlfall, in a European multi-
centre study with over 27000 cases of salmonellosis in
2000, discovered 36% multi drug resistant isolates [4].
Strikingly, in our study almost all MDR isolates lay
within cluster A (Figure 3). Similarities in the resistance
situation between the European Union and Switzerland
indicate a close relationship of strains belonging to clus-
ter A and strains responsible for the high level of resis-
tance in Europe.
A high prevalence of nalidixic acid resistant strains
was found within cluster A, whereas nearly no resistance
to nalidixic acid could be observed among the remaining
isolates. A similar behaviour for resistances to tetracy-
cline, sulfonamide and trimetoprim was noted.
Fluoroquinolones and third-generation cephalosporins
are drugs-of-choice for invasive Salmonella infections.
During the past years numerous studies reported the
emergence of fluoroquinolone or third-generation
cephalosporine resistant strains [9,11,12]. We found a
high prevalence of isolates resistant to nalidixic acid but
no full resistance against ciprofloxacin, and only 2% of
isolates being intermediate over the whole study period.
Because of the intersecting resistance mechanisms
against quinolones and fluoroquinolones, the behaviour
against ciprofloxacin must be discussed in association
with that to nalidixic acid [19]. Because of repeated
reports of fluoroquinolone treatment failure following
disease caused by Salmonella strains that were suscepti-
ble to fluoroquinolones using CLSI criteria, but were
simultaneously resistant to nalidixic acid, several authors
called for re-evaluation of the CLSI breakpoints for
fluoroquinolones involving salmonellae [20-22]. Conse-
quently, comments no. 2, 18, and 20 were added to
Table Two A in CLSI documents, as can be seen, for
instance, in the 2008 edition [15]. They serve as a warn-
ing, that fluoroquinolone-susceptible but nalidixic acid-
resistant extraintestinal salmonellae must be considered
reduced-susceptible to fluoroquinolones. By the com-
ments, the reader is also urged to perform a nalidixic
acid susceptibility test, in order to become aware of
such strains. Based on these arguments, the 62% naldixic
acid-resistant S. Virchow isolates of the present study
have to be considered reduced-susceptible to ciprofloxa-
cin, and thus prone to cause a significant rate of treat-
ment failure. The observation of a low rate of “obvious”
resistance to fluoroquinolones is in accordance with
data from other European countries [4,5]. As we discov-
ered only two ESBL producing isolates in the years 2005
and 2006, the occurrence of such strains in Switzerland
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are rather rare events compared to other European
countries [5,11,23].
In many countries, S. Virchow infections are poultry
associated [6-9]. In Switzerland, however, there is a
favourable situation in poultry flocks with respect to
Salmonella in general and S. Virchow in particular [24].
However, 52% of all poultry meat is imported and 71%
of the imports originate from Brazil, Germany and
France. From all these countries, detection of S. Virchow
in poultry products has been reported [7,25,26]. On this
basis, one might speculate, that a majority of the S.
Virchow infections in Switzerland may be linked to tra-
velling activities and/or consumption of imported poul-
try meat. This, however, would have to be further
investigated by additional case control- and epidemiolo-
gical studies.
Conclusion
The worldwide increase of antibiotic resistances in
Salmonella is an emerging public health problem. For
Switzerland, no clear trend is identifiable over the years
2004 to 2009 for S. Virchow. Antimicrobial susceptibility
and resistance profiles varied considerably within this
period. Nevertheless, the situation in Switzerland coin-
cided with findings in other European countries. Geno-
typing results of this strain collection revealed no
evidence for an undetected outbreak within this time
period.
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